Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Open Access
- 21 July 2023
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (9) , 3709-3716
Abstract
This mirror-image study aimed to evaluate the real-life effectiveness of long-acting injectable antipsychotics (LAI) in schizophrenia. Patients with schizophrenia initiating LAIs January 2015–December 2016 were enrolled from the French National Health Data System (SNDS). Standardized mean differences (SMD > 0.1 deemed clinically significant) were calculated for psychiatric healthcare resource utilization measures assessed one year before (during oral AP treatment) and one year after LAI initiation. LAI effectiveness was analyzed overall and by age group, gender and compliance to oral AP, defined as exposure to an AP for at least 80% of the year before LAI initiation. 12,373 patients were included. LAIs were more frequently initiated in men (58.1%), young (18–34 years, 42.0%) and non-compliant (63.7%) patients. LAI initiation was effective in reducing the number and duration of psychiatric hospitalizations and psychiatric emergency department (ED) admissions in non-compliant patients (SMD = −0.19, −0.26 and −0.12, respectively), but not in compliant patients. First-generation LAIs, paliperidone and aripiprazole LAIs reduced psychiatric hospitalizations (SMD = −0.20, −0.24, −0.21, respectively) and ED admissions (SMD = −0.15, −0.13, −0.15, respectively). No differences in effectiveness were found for age or gender. In compliant patients, only aripiprazole LAI reduced the number of psychiatric hospitalizations (SMD = -0.13). Risperidone and paliperidone LAIs increased hospitalization duration (SMD = 0.15 and 0.18, respectively). The prescription of LAIs (except risperidone) should be recommended in all non-compliant patients, even in women and patients aged 35 or older. The lower frequency of administration of LAIs than of oral APs may improve compliance and hence reduce the risk of relapse. Aripiprazole LAI may represent a treatment of choice for compliant patients that should be further investigated.Keywords
Funding Information
- Otsuka Pharmaceutical Development & Commercialization Inc. H.Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
- Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
This publication has 43 references indexed in Scilit:
- Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyThe British Journal of Psychiatry, 2014
- Aripiprazole versus other atypical antipsychotics for schizophreniaCochrane Database of Systematic Reviews, 2014
- Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illnessBMC Psychiatry, 2013
- Long-Acting Injectable Versus Oral Antipsychotics in SchizophreniaThe Journal of Clinical Psychiatry, 2013
- A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for SchizophreniaAmerican Journal of Psychiatry, 2011
- Comparative Effectiveness of Long-Acting Risperidone in New ZealandClinical Drug Investigation, 2010
- The Expert Consensus Guideline SeriesThe Journal of Clinical Psychiatry, 2009
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational ResearchCommunications in Statistics - Simulation and Computation, 2009
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisThe Lancet, 2009
- Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneEuropean Psychiatry, 2004